Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a chatbot help end HIV? new study tests digital tool in black MSM

NCT ID NCT05968755

First seen Jan 30, 2026 · Last updated Jun 22, 2026 · Updated 24 times

Summary

This study will test a chatbot designed to increase awareness and use of PrEP, a daily pill that prevents HIV, among Black men who have sex with men (MSM) in the Southern United States. About 145 participants will interact with the chatbot over 90 days, answering questions and receiving personalized PrEP information. The goal is to see if the chatbot can help more men learn about and start taking PrEP, potentially reducing HIV rates in this high-risk group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREP UPTAKE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Care 4 U Community Health Center

    Miami, Florida, 33127, United States

  • Community Care Resources of FL (CCRSFL)

    Pembroke Pines, Florida, 33027, United States

  • NAESM, Inc

    Atlanta, Georgia, 30318, United States

  • RAO Community Health

    Charlotte, North Carolina, 28202, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

chatbot

What this could lead to

If successful, this chatbot could become a low-cost tool to increase PrEP use and reduce HIV rates in a high-risk community.

What could go wrong

This is a small, early-stage trial with no control group, so results may not be generalizable. The chatbot's impact on actual HIV prevention is uncertain.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.